title: CHOP or THP-COP regimens in the treatment of newly diagnosed peripheral T-cell lymphoma, not otherwise specified: a comparison of doxorubicin and pirarubicin.
abstract: The CHOP regimen consisting of cyclophosphamide, doxorubicin (DOX), vincristine and prednisolone has been the most used regimen for peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS). Pirarubicin [tetrahydropyranyladriamycin (THP)], a derivative of DOX, is an anthracycline with reportedly less cardiotoxicity than DOX. Here, we confirmed the efficacy of THP-COP using THP instead of DOX in the treatment of PTCL-NOS. The study protocol employed a retrospective, consecutive entry design. We retrospectively analysed 56 patients with PTCL-NOS who had received THP-COP or CHOP. These regimens were performed every 21 days. Twenty-nine patients received THP-COP, and 27 received CHOP. There were no significant differences in known prognostic factors, including in the International Prognostic Index (IPI) and the prognostic index for T-cell lymphoma (PIT), between the two groups. Complete remission rates in patients with THP-COP and CHOP were 52% in both groups; the 3-year overall survival (OS) rates were 67% and 52% (p = 0.074), and the 3-year progression-free survival (PFS) rates were 51% and 29% (p = 0.070), respectively. In patients with low IPI (low or low-intermediate), THP-COP had significantly better 3-year OS (100% vs. 64%; p < 0.001) and 3-year PFS (75% vs. 33%; p < 0.05) than CHOP. Similar differences between THP-COP and CHOP were observed in patients with a low PIT (groups 1 or 2). Our study showed that THP-COP produced results equivalent to CHOP regarding efficacy and safety in patients with PTCL-NOS. In patients with low IPI or PIT, THP-COP resulted in significantly better prognosis. Copyright © 2015 John Wiley & Sons, Ltd.
authors.affiliation: Department of Hematology, Gifu University Graduate School of Medicine, Gifu, Japan.
authors.forename: Yuhei
authors.initials: Y
authors.lastname: Shibata
authors.affiliation: Department of Hematology, Gifu University Graduate School of Medicine, Gifu, Japan.
authors.forename: Takeshi
authors.initials: T
authors.lastname: Hara
authors.affiliation: Department of Hematology, Gifu Municipal Hospital, Gifu, Japan.
authors.forename: Senji
authors.initials: S
authors.lastname: Kasahara
authors.affiliation: Department of Hematology, Gifu Prefectural General Medical Center, Gifu, Japan.
authors.forename: Toshiki
authors.initials: T
authors.lastname: Yamada
authors.affiliation: Department of Hematology, Japanese Red Cross Gifu Hospital, Gifu, Japan.
authors.forename: Michio
authors.initials: M
authors.lastname: Sawada
authors.affiliation: Department of Hematology, Gifu University Graduate School of Medicine, Gifu, Japan.|Department of Internal Medicine, Kisogawa Municipal Hospital, Gifu, Japan.
authors.forename: Ryoko
authors.initials: R
authors.lastname: Mabuchi
authors.affiliation: Department of Hematology, Gifu University Graduate School of Medicine, Gifu, Japan.
authors.forename: Takuro
authors.initials: T
authors.lastname: Matsumoto
authors.affiliation: Department of Hematology, Gifu University Graduate School of Medicine, Gifu, Japan.
authors.forename: Nobuhiko
authors.initials: N
authors.lastname: Nakamura
authors.affiliation: Department of Hematology, Gifu University Graduate School of Medicine, Gifu, Japan.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Nakamura
authors.affiliation: Department of Hematology, Gifu University Graduate School of Medicine, Gifu, Japan.
authors.forename: Soranobu
authors.initials: S
authors.lastname: Ninomiya
authors.affiliation: Department of Hematology, Gifu University Graduate School of Medicine, Gifu, Japan.
authors.forename: Junichi
authors.initials: J
authors.lastname: Kitagawa
authors.affiliation: Department of Hematology, Gifu University Graduate School of Medicine, Gifu, Japan.
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Kanemura
authors.affiliation: Department of Pathology and Translational Research, Gifu University Graduate School of Medicine, Gifu, Japan.
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Kito
authors.affiliation: Department of Hematology, Gifu University Graduate School of Medicine, Gifu, Japan.
authors.forename: Naoe
authors.initials: N
authors.lastname: Goto
authors.affiliation: Pathology Division, Gifu University Hospital, Gifu, Japan.
authors.forename: Tatsuhiko
authors.initials: T
authors.lastname: Miyazaki
authors.affiliation: Department of Pathology and Translational Research, Gifu University Graduate School of Medicine, Gifu, Japan.
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Takami
authors.affiliation: Department of Pathology and Translational Research, Gifu University Graduate School of Medicine, Gifu, Japan.
authors.forename: Tamotsu
authors.initials: T
authors.lastname: Takeuchi
authors.affiliation: Department of Hematology, Gifu University Graduate School of Medicine, Gifu, Japan.
authors.forename: Masahito
authors.initials: M
authors.lastname: Shimizu
authors.affiliation: Department of Hematology, Gifu University Graduate School of Medicine, Gifu, Japan.
authors.forename: Hisashi
authors.initials: H
authors.lastname: Tsurumi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage; D011379:Prognosis; D012189:Retrospective Studies; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; C027260:pirarubicin
keywords: doxorubicin; non-Hodgkin's lymphoma; peripheral T-cell lymphoma not otherwise specified (PTCL-NOS); pirarubicin